Stockreport

Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU) [Yahoo! Finance]

Novartis AG  (NVS) 
Last novartis ag earnings: 4/28 01:00 am Check Earnings Report
US:NYSE Investor Relations: novartis.com/investors
PDF Novartis Pharma AG Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe Improvements with remibrutinib [Read more]